Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 683-690 , December 2008

Diagnosis and therapy of fungal infection in patients with leukemia—new drugs and immunotherapy

  • Elias J. Anaissie, MD (Deputy Chair)

      Affiliations

    • Corresponding Author InformationTel.: +501 526 2873; Fax: +501 686 6442.

References 

  1. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine. 1998;77:246–254
  2. Sulahian A, Boutboul F, Ribaud P, et al. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematology units during a 4-year prospective study. Cancer. 2001;91:311–318
  3. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer. 2007;110:830–834
  4. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clinical Infectious Diseases. 2008;46:1412–1422
  5. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer. 2007;110:112–120
  6. Mahfouz T, Miceli MH, Saghafifar F, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. Journal of Clinical Oncology. 2005;23:7857–7863
  7. Franzius C, Biermann M, Hulskamp G, et al. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clinical Nuclear Medicine. 2001;26:232–233
  8. Kok J, Gilroy N, Halliday C, et al. Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae. The Journal of Infection. 2007;55:e33–e36
  9. Stark D, Milliken S, Marriott D, et al. Rhizopus microsporus var. rhizopodiformis sinus-orbital zygomycosis in an immunosuppressed patient: successful treatment with posaconazole after a complicated clinical course. Journal of Medical Microbiology. 2007;56:699–701
  10. Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrobial Agents and Chemotherapy. 2006;50:1993–1999
  11. Gubbins P, Mcconnell S, Amsden J, Anaisssie EJ. Comparison of liposomal amphotericin B plasma and tissue concentrations following a single large (15mg/kg) dose or daily 1mg/kg dosing. 44th. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Sept 30-Nov 2, 2004.
  12. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004 Nov 15;39(10):1407–1416Epub 2004 Oct 27
  13. Fritz JM, Brielmaier BD, Dubberke ER. Micafungin for the prophylaxis and treatment of Candida infections. Expert Review of Anti-Infective Therapy. 2008;6:153–162
  14. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007 Jan 25;356(4):348–359
  15. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457–462
  16. Dignani MC, Rex JH, Chan KW, et al. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer. 2005;104:199–204
  17. Grigg A, Slavin M. Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy. Transplant Infectious Disease. 2008;10:3–12
  18. Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia. 1997;11:1621–1630

PII: S1521-6926(08)00089-3

doi: 10.1016/j.beha.2008.10.001

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 683-690 , December 2008

Article Tools

* Image Usage & Resolution